Loading...
  • relapse
  • Although GS relapse of CML is accepted as a highly refractory disease and a combination chemoradiotherapies with or without second allogeneic transplantation is usually preferred, little is known about predisposing factors, natural history, and response to treatment of these patients as compared to marrow relapse. (hindawi.com)
  • Secondary analyses will consider neutrophil and platelet recovery, acute and chronic GVHD, time off all immunosuppressive therapy, relapse, infections, adverse events and immune reconstitution. (knowcancer.com)
  • Patients
  • Patients with responsive disease may receive an additional 2 months of therapy. (clinicaltrials.gov)
  • It was subsequently reported in rare patients with solid organ malignancies, granulomatous and inflammatory diseases, solid organ transplant recipients, and with the use of certain drugs. (uptodate.com)
  • An increase of the CMR rate could possibly translate in a higher proportion of patients candidate to stopping anti-CML treatment, with higher probability of remaining disease-free in the long term. (clinicaltrials.gov)
  • disorder
  • FLT3-ITDs induced an oligoclonal myeloproliferative disorder in mice, characterized by splenomegaly and leukocytosis. (jove.com)
  • These results demonstrate that FLT3-ITD mutant proteins are sufficient to induce a myeloproliferative disorder, but are insufficient to recapitulate the AML phenotype observed in humans. (jove.com)
  • lymphoma
  • Thoroughly UPDATED chapters cover the most recent changes in the clinical management of melanoma, mast cell tumors, tumors of the skeletal system, tumors of the endocrine system, tumors of the mammary gland, urinary cancers, nervous system cancers, lymphoma, and histiocytic diseases. (a3shop.hu)
  • malignant
  • For many in the healthcare system, it has become obvious that, even in the richest of countries, it is now impossible to pay for all cancer treatments for all people and that environmental and lifestyle causes of malignant disease have to be controlled if we want to keep it in check. (ecancer.org)
  • cells
  • So, the discovery of hiPSCs opens new opportunities in biomedical sciences, since these cells may be useful for understanding the mechanisms of diseases in the production of new diseases models, in drug development/drug toxicity tests, gene therapies, and cell replacement therapies. (hindawi.com)
  • Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. (hindawi.com)
  • drug
  • By changing these genes, the drug may help to stop them from causing the disease to grow. (clinicaltrials.gov)
  • You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. (clinicaltrials.gov)
  • dependent
  • It is context dependent, relying in part on the disease, studied patient population, therapeutic mechanism of action, and availability of current treatments. (fda.gov)
  • diagnosis
  • Since it is a very aggressive disease with a poor prognosis, combined chemoradiotherapies with other possible options like DLI or second allogeneic SCT should be considered as soon as the diagnosis is confirmed. (hindawi.com)